Shots:

• Novartis gets an exclusive WW right to develop and commercialize therapeutic applications for FAP assets including FAPI-46 and FAPI-74 under its collaboration with iTheranostics- which is an affiliate of SOFIE Biosciences
• The agreement also consists of co-exclusive rights for Novartis to develop imaging applications for FAP assets
• The company will continue to reimagine cancer care through the development of a robust radioligand therapy portfolio and actively investigate across multiple tumor types

  Ref: Novartis | Image: Novartis